The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and ...

A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...

Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...